Biomarker results from PENELOPE, A randomised phase III trial evaluating chemotherapy (CT) +/- pertuzumab (P) for platinum-resistant ovarian cancer (PROC) with low tumor HER3 mRNA expression

ONCOLOGY RESEARCH AND TREATMENT(2016)

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要